Company: CPMV
Filing Date: 2025-11-12
Form Type: NT 10-Q
Source: 0001683168-25-008256
Chunk: 1

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-11-12
Form: NT 10-Q
Chunk 1
---
 or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and |
|   | -c | The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.                                                                                                                                                                                                                                                                                                                                                             |

PART III - NARRATIVE

State below in reasonable detail the
reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof could not be filed within the
prescribed time period.

Mosaic ImmunoEngineering, Inc., a
Delaware corporation (the “Company”), was unable, without unreasonable effort or expense, to file its Quarterly Report on
Form 10-Q for the quarter ended June 30, 2025 (the “Form 10-Q”) by the prescribed deadline of 5:30 p.m. EDT on August 14,
2025 because additional time, resources and effort are required to complete work related to the Company’s financial reporting and
close procedures. The Company expects to file its Form 10-Q as soon as possible, but no later than the fifth calendar day following the
prescribed due date.

PART IV - OTHER INFORMATION

(1) Name and telephone number of person to contact
in regard to this notification:

| Steven King |     |        657 |     | 208-0890       |
| (Name)      |     | -Area Code |     | -Telephone No. |

(2) Have all other periodic reports required under
section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12
months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).
☒ Yes ☐
No

(3) Is it anticipated that any significant change
in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included
in the subject report or portion thereof? ☐ Yes ☒
No

If so, attach an explanation of the anticipated
change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be
made.

| 2 |

<div align='center'>Mosaic ImmunoEngineering, Inc.

(Name of Registrant